Literature DB >> 31500782

Quality of life in patients with upper GI malignancies managed by a strategy of chemoradiotherapy alone versus surgery.

Lauren O'Connell1, Mary Coleman2, N Kharyntiuk2, Thomas N Walsh3.   

Abstract

BACKGROUND AND OBJECTIVES: Neoadjuvant chemoradiotherapy (nCRT) induces a pathological complete response (pCR) in 25-85% of oesophago-gastric cancer. As surgery entails morbidity and mortality risks and quality of life (QL) impairment, its avoidance in patients without residual disease is desirable. This study aimed to compare quality of life of patients with a cCR who chose surveillance with those who chose surgery.
METHODS: Four groups of patients were studied. Group 1(n = 31) were controls; Group 2 (n = 26) had chemoradiotherapy only; Group 3 (n = 31) had oesophagectomy after nCRT; Group 4 (n = 26) had gastrectomy alone. A 33-point novel questionnaire was administered at two 3 month time points. Participants were also interviewed with a validated questionnaire.
RESULTS: Mean(±sd) quality of life scores in cCR patients offered surveillance (28.9 ± 4.5) were superior to patients undergoing oesophagectomy (32.3 ± 58. p=0.042) or gastrectomy (33.19 ± 5.9, p=0.004). This result was replicated in the validated questionnaire (p=0.017). There was a trend towards increased reflux-related respiratory symptoms in the oesophagectomy group (7.3 ± 2.2 vs 6.5 ± 1.9; p=0.396) and towards early dumping (8.2 ± 1.4 vs 7.1 ± 1.; p=0.239) and vagotomy-related symptoms (1.82 ± 0.9 vs 1.4 ± 0.6; p=0.438) in the gastrectomy group.
CONCLUSIONS: Avoidance of surgery in cCR patients is rewarded with a superior quality of life to those undergoing surgery.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chemoradiotherapy; Gastric cancer; Oesophageal cancer; Organ preservation; Quality of life; Surgery

Mesh:

Year:  2019        PMID: 31500782     DOI: 10.1016/j.suronc.2019.05.021

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  2 in total

1.  Surveillance of Clinically Complete Responders Using Serial 18F-FDG PET/CT Scans in Patients with Esophageal Cancer After Neoadjuvant Chemoradiotherapy.

Authors:  Maria J Valkema; Berend J van der Wilk; Ben M Eyck; Bas P L Wijnhoven; Manon C W Spaander; Michail Doukas; Sjoerd M Lagarde; Wendy M J Schreurs; Mark J Roef; J Jan B van Lanschot; Roelf Valkema
Journal:  J Nucl Med       Date:  2020-09-04       Impact factor: 11.082

2.  Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed: The Study Protocol for the Randomized Controlled NEEDS Trial.

Authors:  Magnus Nilsson; Halla Olafsdottir; Gabriella Alexandersson von Döbeln; Fernanda Villegas; Giovanna Gagliardi; Mats Hellström; Qiao-Li Wang; Hemming Johansson; Val Gebski; Jakob Hedberg; Fredrik Klevebro; Sheraz Markar; Elizabeth Smyth; Pernilla Lagergren; Ghazwan Al-Haidari; Lars Cato Rekstad; Eirik Kjus Aahlin; Bengt Wallner; David Edholm; Jan Johansson; Eva Szabo; John V Reynolds; C S Pramesh; Naveen Mummudi; Amit Joshi; Lorenzo Ferri; Rebecca Ks Wong; Chris O'Callaghan; Jelena Lukovic; Kelvin Kw Chan; Trevor Leong; Andrew Barbour; Mark Smithers; Yin Li; Xiaozheng Kang; Feng-Ming Kong; Yin-Kai Chao; Tom Crosby; Christiane Bruns; Hanneke van Laarhoven; Mark van Berge Henegouwen; Richard van Hillegersberg; Riccardo Rosati; Guillaume Piessen; Giovanni de Manzoni; Florian Lordick
Journal:  Front Oncol       Date:  2022-07-13       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.